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Fumonisins are produced by Fusarium
moniliforme Sheldon (= F. verticillioides), F.
proliferatum, and other Fusarium species
(1–4). They were discovered by Gelderblom
et al. (5) in 1988, and their natural occur-
rence in corn was demonstrated soon there-
after (6–10). Fumonisin B1 (FB1) is the most
common homologue (Figure 1); however, a
growing number of other homologues and
derivatives have been described. Fumonisins
have worldwide distribution in corn and
occur in corn-based feeds and foods. A com-
prehensive review of this subject by Dutton
has been published (11). Equine leuko-
encephalomalacia (ELEM) and porcine pul-
monary edema, fatal toxicoses associated with
the consumption of (F. moniliforme) moldy
feed by horses (12,13) and swine (13), respec-
tively, have been experimentally reproduced
using puriﬁed FB1 (14–18).
The impact of fumonisins on human
health remains unclear but is of concern.
Consumption of F. moniliforme-molded,
home-grown corn has been correlated with
high esophageal cancer rates in areas of south-
ern Africa (19–21) and central China (22), and
comparatively high fumonisin concentrations
are found in the corn from these high
esophageal cancer areas (4,23–28). It has also
been suggested that fumonisins are a risk factor
for liver cancer (29), and FB1, like some F.
moniliforme isolates (30,31), was hepatocar-
cinogenic when fed (50 ppm) to male BD IX
rats (32). Studies are limited, but hepatotoxicity
and atherogenic serum lipid proﬁles, perhaps
secondary to liver dysfunction, were found in
nonhuman primates fed diets containing
fumonisin (13,33,34). Finally, a possible link
between fumonisin exposure and neural tube
defects in humans has been proposed (35).
In vivo investigations using rodents and
rabbits have contributed significantly to
F. moniliforme and fumonisin research.
Fumonisins were discovered using an in vivo
liver bioassay (5). Data from subchronic toxi-
city studies have been used in preliminary risk
evaluations (36,37), have been useful for
developing protocols for chronic studies, and
have otherwise increased our understanding
of these compounds. An overview of toxicity
and other important data obtained during in
vivo investigations follows. 
Absorption, Biodistribution,
and Pharmacokinetics 
Fumonisins are poorly absorbed and rapidly
eliminated; small amounts accumulate in liver
and kidneys (Table 1). Norred et al. (38)
recovered 80% of the radiolabel from feces
within 48 hr and ≤ 3% from urine within 96
hr after giving a single oral dose of [14C]FB1
(0.045 µCi) to rats. Small but relatively con-
stant amounts of radiolabel were found in liver
(about 0.4% of the dose) and kidney (about
0.1% of the dose) up to 96 hr postdosing.
After administering the same dose for 3 con-
secutive days to rats, more than 75% of the
[14C] was excreted in feces and about 4% in
urine within 72 hr of the last dose. Liver- and
kidney-speciﬁc activities peaked 24 hr after the
last dose, but persisted for another 48 hr. Like
FB1, fumonisin B2 (FB2) is also rapidly cleared
from plasma and excreted (82% within 72 hr,
mostly during the ﬁrst 24 hr), predominantly
in the feces (39). Only about 1% of the dose
was recovered in the urine.
Liver and kidney accumulated relatively
high amounts of [14C]FB1 following
intraperitoneal (ip) or intravenous (iv) dosing
to rats (Table 1). Up to 66% of the radiolabel
appeared in feces, suggesting that FB1 (or
possibly a metabolite) is excreted in bile. This
was confirmed by Shephard et al. (40) who,
within 4 hr of giving 7.5 mg/kg body weight
(bw) [14C]FB1 ip to cannulated rats, recov-
ered about 67% of the dose as unchanged
FB1 in the bile. In contrast, only 0.2% of the
radiolabel was recovered in bile following oral
administration of the same dose (7.5 mg/kg
bw [14C]FB1), further suggesting that gas-
trointestinal absorption of FB1 by rats is low.
Little pharmacokinetic data is available.
Shephard et al. calculated time of plasma
maximum concentration (Tmax) of about 20
min, peak plasma concentration (Cmax) of 8.6
µg/mL, and a serum elimination half-life
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(T1/2) of approximately 18 min for rats
following a single ip injection of 7.5 mg/kg
FB1 (41). Tmax, Cmax, and T1/2 of FB2 are
similar (Table 1). There have been no reports
of fumonisin metabolism by the liver, kidney,
or other tissues, although the intestinal ﬂora
of the rat, like that of the nonhuman primate
(42), hydrolytically removes the tricarballylic
acid groups from fumonisin’s hydrocarbon
backbone (43).
Toxicology: Subchronic Effects
of Fumonisins in Rats 
Fumonisins, F. moniliforme, and 
in Vivo Toxicity 
Fumonisins are fungal products. Therefore,
the relationship between fumonisin toxicity
and toxicity of the fungi should be kept in per-
spective. Not all fungi identiﬁed as F. monili-
forme are toxic. For example, culture material
(0, 4, 8, or 16% w/w in the diet) of isolate
MRC 826 caused signiﬁcant dose-related toxi-
city and liver pathology (kidney was not exam-
ined) when fed to rats for 4 weeks, whereas
isolate RRC 415 culture material was without
effect (44). Similarly, only 3 of 11 F. monili-
forme isolates induced γ-glutamyl transpepti-
dase (GGT)-positive liver foci in rats (45).
MRC 826 culture material (0.5% in the diet),
but not a 10-fold higher dietary concentration
of isolate MRC 1069 culture material, caused
hepatocarcinomas in rats (30). It has been
shown that MRC 826 is a fumonisin producer
(46), but that both MRC 1069 (30) and RRC
415 (47) produce predominantly fusarin C.
Additionally, F. moniliforme produces
other biologically active, potentially toxic
compounds including fusariocins (48), the
mutagen fusarin C, other fusarins (49,50),
and fusaric acid (51). None of these have
reproduced the in vivo effects of toxic F.
moniliforme isolates (30,52–54). Conversely,
the link between F. moniliforme and fumon-
isin has been independently established by
several research groups; that is, the in vivo tox-
icities of corn (involved in ELEM outbreaks)
naturally contaminated with F. moniliforme
(9,55), culture materials of (toxic) F. monili-
forme isolates, polar culture material extracts,
and purified FB1 are qualitatively the same
(5,32,45,56–61). FB2, fumonisin B3 (FB3),
and probably also hydrolyzed FB1 (HFB1)
exert the same in vivo effects (62–64).
Hepatotoxicity 
Histopathologic effects in rats, which have
been referred to by various terms such as
hepatopathy, hepatosis, or toxic hepatitis,
have been reported by several research groups.
Their descriptions are consistent, differing
only in detail and nomenclature (5,56–58,
61,65–67). The initial finding is small,
rounded, eosinophilic hepatocytes that appear
to have pulled away from neighboring cells.
The chromatin of these cells is irregularly
condensed and marginated or may be frag-
mented. Inflammatory response is absent to
minimal. Although their appearance is consis-
tent with apoptosis, these cells were com-
monly described as single-cell necrosis until
their apoptotic nature was histochemically
confirmed by Tolleson et al. (61) and
Howard et al. (68,69). This does not mean,
however, that necrosis (oncotic necrosis in the
traditional sense, as opposed to programmed
cell death or apoptosis) does not play a role in
fumonisin-induced hepatotoxicity. Necrotic
hepatocytes are also present early-on. Serum
chemical indications of hepaocellular injury,
including increased alanine and aspartate
transaminase, alkaline phosphatase, and lac-
tate dehydrogenase activities, as well as
increased cholesterol and triglyceride concen-
trations (Figure 2), are routine, early ﬁndings.
As tissue injury progresses, both apoptotic
and necrotic cells increase in number, mitotic
figures appear with increasing frequency,
hepatocellular cytoplasm becomes increas-
ingly vacuolated, and cytomegaly with vari-
ability in cell and nuclear size becomes
obvious. Bile duct and oval cell proliferation,
foci of cellular alteration, cholangiomatous
lesions, and ﬁbrosis occur in long-standing or
advanced lesions, giving a picture of nodular
regeneration or cirrhosis (32). Females are
generally more sensitive than males (Table 2).
Along with the aformentioned clinical chemi-
cal indicators, which continue to rise, serum
GGT activity and bilirubin concentration
increase as liver injury becomes more severe. 
Fumonisins induced both GGT and the
placental form of glutathione S-transferase
(GSTP)-positive foci in BD IX and Fischer
rats (5,62,70,71). Foci induction in diethyl-
nitrosamine-pretreated Fischer rats was dose
related, and GSTP was a more sensitive
marker than GGT (Figure 3) (70). From these
and other data, Gelderblom et al. (72) pro-
posed that FB1 was a tumor promoter at doses
not causing significant liver pathology, but
when given at overtly hepatotoxic doses, it was
also a weak initiator. FB1 (50 ppm) caused
marked nonneoplastic changes (cirrhosis) and
hepatocellular carcinomas when fed to BD IX
males for 20 months or more (32). Relatively
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Figure 1. Chemical structure of FB1.
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Figure 2. Selected serum chemical effects of FB1.
Abbreviations: ALT, alanine aminotransferase; AST,
aspartate aminotransferase. Serum ALT and AST activi-
ties, international units/deciliter cholesterol, and mil-
ligrams per deciliter triglycerides were significantly
increased (p < 0.05) in male Sprague-Dawley rats fed
150 ppm FB1 for 4 weeks. Data from Voss et al. (58).
Table 1. Selected studies on the bioavailability of fumonisins in rats following iv or ip dose administration.
Strain (sex) Dosing Findings Reference
BD IX (male) 7.5 mg/kg [14C]FB1, After 24 hr: 66% of dose recovered in feces; 32% (120) 
single dose, ip recovered in urine; 1% found in liver; traces remained 
in kidney and blood cells.
Wistar (male),  7.5 mg/kg [14C]FB1,  After 24 hr: about 67% of dose recovered in bile, mostly  (121)
bile duct cannulated  single dose, ip (approximately 60% of dose) within the ﬁrst 4 hr.
Sprague-Dawley 0.0045 µCi [14C]FB1, 14C appears in gastrointestinal tract (peaking at approxi- (38)
(male) single dose, iv mately 10% of dose after 1 hr); feces (approximately 35% 
of dose recovered after 96 hr); urine (approximately 10% 
recovered after 12–96 hr); liver (approximately 45 and 
25% of dose found after 1 and 96 hr, respectively); and 
kidney (approximately 10% of dose from 10 min to 96 hr).
Sprague-Dawley 0.145  µCi  [14C]FB1, After 1 hr: about 45% of dose recovered in gastrointestinal  (106)
(female), pregnant single dose, iv tract, mostly in feces; liver and kidney contain about 14.5 
on GD 15 and 4.0% of dose, respectively; only 1.2% of dose found 
in blood.
BD IX (males) 7.5 mg/kg FB2,  Tmax approximately 20 min; Cmax = 3.5 µg/mL; serum T1/2 of (39) 
single dose, ip approximately 26 min. Concentration peaks in plasma 10 min 
after injection, followed by rapid elimination; approximately 
1 and 84% of dose recovered from urine and feces,  
respectively, through 72 hr, mostly within ﬁrst 24 hr.
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(marginally deficient) low dietary lipotrope
levels may have contributed to the neoplastic
response. Nonetheless, these results demon-
strated carcinogenicity by FB1 and the need for
further studies. One such study, the recently
completed chronic bioassay by the National
Center for Toxicological Research of the U.S.
Food and Drug Administration (73), showed
that FB1 was a kidney carcinogen in rats and a
liver carcinogen in mice, respectively.
Nephrotoxicity
The kidney was the most sensitive target
organ in Sprague-Dawley and Fischer 344
rats fed FB1 for up to 90 days (Table 2)
(57,58,61,74) or given FB1 by gavage or ip
injection for 4–11 days (65–67,75). Males
were more sensitive than females. In contrast,
Gelderblom et al. (5,32) described hydropic
degeneration, occasional necrosis, and a few
other renal abnormalities in their studies in
BD IX rats, but did not refer to the kidney as
a target organ. This suggests that significant
differences in response to fumonisins may
exist among various rat strains.
As in liver, apoptosis is the initial micro-
scopic finding in kidney. Apoptotic cells are
initially found almost exclusively in tubules of
the outer medulla (designated “cortico-
medullary junction” in some publications).
Many of the apoptotic cells appear rounded
and detached from adjacent cells and the
basement membrane. Mitotic ﬁgures appear,
and the number of apoptotic cells increases in
the tubule epithelium as injury progresses.
Cytoplasmic vacuolation and basophilia,
decreased cellular height, and alterations in
nuclear size and staining become evident. At
this point, lesions may extend deeper into the
medulla or into the cortex, and epithelial cells
are sloughed into the tubular lumina. Thus,
there is simultaneous cell loss and replace-
ment revealed on three levels: on the cellular
level by apoptosis and mitosis, on the histo-
logic level by tubular atrophy and hyperplasia
(regeneration), and grossly by decreased kid-
ney weight (Figure 4). The failure of regener-
ation to keep pace with cell loss may be quite
important, as imbalances between cell loss
and replacement in tissues may be a signifi-
cant contributor to carcinogenesis (76–78).
Increased serum creatinine, decreased
CO2 and, less often, increased urea nitrogen
occur in FB1-treated rats (57,58,79).
Increased activities of N-acetyl-β-glucos-
aminidase, GGT, and lactate dehydrogenase
have been found in urine, giving further clini-
cal evidence of tubular injury (65,75).
Proteinuria may also occur and, because of
the presence of high-molecular-weight pro-
teins in the urine, it has been suggested that
FB1 may also cause glomerular injury (75).
Alternatively, sloughed tubule cells, which
can be numerous in urine, are a more likely
cause of proteinuria (80).
There is little data on renal function in
fumonisin-treated animals. Urinary output
and water consumption were increased in
male rats fed F. moniliforme culture material
(64). These observations were consistent with
those of Bondy et al. (65,67) and Suzuki et al.
(75), who studied renal function in rats given
daily ip doses (7.5–10 mg/kg for 4 days) or
oral doses (1–75 mg/kg for 11 days) of FB1.
Signs of renal dysfunction in these animals
included increased output of hypoosmotic
urine, increased urinary enzyme levels, pro-
teinuria, increased serum Mg2+ and Ca2+ con-
centrations, and decreased anion
(p-aminohippurate, up to 80% reduction) and
cation (tetraethylammonium, up to 40%
reduction) transport by renal cortex slices.
Interestingly, some indications of renal dys-
function peaked on days 6–8 of the 11-day
exposure period (67), suggesting that
fumonisin-damaged kidneys have some
functional adaptive capacity.
Other in Vivo Toxicologic Findings 
in Rats
There are indications that the immune system
may be a target. Bondy et al. (66) found dis-
seminated thymic necrosis with decreased
thymic weight and increased serum IgM con-
centrations in FB1-exposed rats. Others found
that the immune responses to sheep red blood
cells and to splenic clearance of Listeria mono-
cytogenes were slightly decreased in rats given
15 (L. monocytogenes) or 25 (sheep red blood
cells) mg/kg bw FB1 for 14 days (81).
Testicular tubule epithelial degeneration
(59), decreased heart weight (54), adrenal
cortex hypertrophy, and cytoplasmic vacuola-
tion (consistent with Zona fasciculata lipoido-
sis and probably a nonspeciﬁc stress response)
(64), cytoplasmic vacuolation of myeloid pre-
cursor cells in bone marrow, and other hema-
tologic ﬁndings (66) have been found in rats
given fumonisins or F. moniliforme culture
materials. Little toxicologic importance has
yet been given to any of these observations. 
Because of the human health implications,
esophageal effects of fumonisins are of special
interest. Marasas et al. (31) found basal cell
hyperplasia of the esophagus in rats fed F.
moniliforme culture material. Others have
noted a transient increase in the 5-bromo-2´-
deoxyuridine labeling index in esophageal
epithelium 3 days following an iv injection of
1.25 mg/kg bw (82), which suggests that FB1
may be mitogenic under some conditions.
However, there is no evidence from sub-
chronic (5,57,58,61) or chronic (32,73) feed-
ing studies of puriﬁed FB1 that the esophagus
is a target organ. Furthermore, FB1 (5 mg/kg
bw/day for 5 weeks) had no effect on the
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Table 2. Dose responsea in liver and kidney: subchronic feeding studies of FB1 in rats.
Liver Kidney
Strain  Study duration Doses (ppm FB1) Males Females Males Females Reference
Sprague-Dawley 28 days 0, 15, 50, 150 50 < NOEL < 150 50 < NOEL < 150 NOEL < 15 15 < NOEL < 50 (58)
Fischer 344 90 days 0, 1, 3, 9, 27, 81 81 < NOEL 27 < NOEL < 81 3 < NOEL < 9 27 < NOEL < 81 (57)
Fischer 344 28 days 0, 99, 163, 234, 484 163 < NOEL < 234 99 < NOEL < 163 NOEL < 99 99 < NOEL < 163 (61)
aNOEL (no-observed-effect level) as deﬁned by histopathology and other ﬁndings.
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Figure 3. Dose-related induction of GGT and the placen-
tal form of GSTP-positive foci in liver of male Fischer
344 rats (n = 5/group). The animals were fed diets with
up to 500 ppm FB1 for 3 weeks, beginning 2 weeks after
pretreatment with 200 mg/kg diethylnitrosamine (ip
injection). The number of GGT and GSTP foci per square
centimeter was significantly increased (p < 0.05) at
≥ 250 ppm and ≥ 100 ppm FB1, respectively; the percent
area involved per liver section was significantly
increased (p < 0.05) at ≥ 100 ppm and ≥ 500 ppm FB1,
respectively. Figure adapted from the data of
Gelderblom et al. (70). 
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Figure 4. Relative (% bw) kidney weight was signifi-
cantly (p < 0.05) decreased in male Sprague-Dawley rats
(n = 5/group) fed 15, 50, or 150 ppm FB1 for 4 weeks.
Significant differences in relative kidney weight were
not found in females; however, absolute kidney weight
(g) of females fed 150 ppm was signiﬁcantly lower than
control values (not shown). Data from Voss et al. (58). 
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number of esophageal papillomas produced in
rats concurrently given the esophageal car-
cinogen N-methylbenzylnitrosamine (83).
Thus, there is no evidence from rodent studies
that FB1 is an esophageal carcinogen, and the
possibility that F. moniliforme produces other
potentially (esophageal) carcinogenic
compounds should not be dismissed. 
Hepatic and Renal Toxicity 
in Other Laboratory Species
Liver and kidney are also targets in mice
(74,84,85). The pathology is similar to that
seen in rats, and females are more sensitive to
hepatotoxicity than males. Apoptosis, hepato-
cellular hyperplasia, bile canaliculi hyperpla-
sia, and Kupffer cell hyperplasia were the
principal findings in females (B6C3F1) fed
≥ 99 ppm FB1 and males fed 484 ppm FB1
for 4 weeks (68,73). A hepatocellular cyto-
plasmic alteration described as reduced cyto-
plasm, basophilia, and loss of cytoplasmic
vacuoles was found in both sexes fed ≥ 99
ppm. Histopathology ﬁndings (hepatopathy)
in female B6C3F1 mice fed 81 ppm FB1 for
90 days (57) were characterized by apoptosis
(= single-cell necrosis), cytomegaly, increased
mitotic ﬁgures, scant inﬂammatory inﬁltrates,
and pigmented macrophages. Serum chemical
indications of hepatic injury of the same type
found in rats also occurred. 
Compared to rats, mice are resistant to
nephrotoxicity. No kidney lesions were found
in mice fed diets with 81 ppm FB1 for 90 days
(57) or diets with 484 ppm FB1 for 28 days
(68). However, when given at relatively high
doses by oral or parenteral routes, FB1 is
nephrotoxic, as illustrated by the ﬁndings of
Sharma et al. (84). They found terminal
deoxynucleotidyl transferase-mediated nick-
end labeling (TUNEL)-positive cells in the
renal tubules of males (females were not exam-
ined) given subcutaneous injections of FB1 for
5 consecutive days (Figure 5). Findings were
corroborated by the dose-related increase in
apoptotic cells, which was found during rou-
tine microscopic examinations (hematoxylin
and eosin sections). Bondy et al. (85) found
slight increases in single-cell necrosis (= apop-
tosis) in the renal tubules of female but not
male B6C3F1 mice given 15–75 mg/kg FB1
by gavage for 14 days. 
Rabbits are quite sensitive to FB1 (86). As
in male rats, the kidney is a more sensitive
target organ than liver. Morphologic, serum
chemical, and tissue sphingolipid findings
were similar to those seen in rodents.
Fumonisins and Sphingolipids:
Mechanistic Considerations 
The preponderance of experimental evidence,
including evaluations of unscheduled DNA
synthesis, Salmonella typhimurium mutagenic-
ity, SOS response in Escherichia coli, mitotic
index, and micronucleus formation [reviewed
by Howard (87)], suggests that fumonisins
exert their effects through a nongenotoxic
mode of action. A signiﬁcant breakthrough in
understanding these compounds occurred
when Wang et al. (88) discovered that
fumonisins inhibit the enzyme ceramide syn-
thase [sphinganine (sphingosine)-N-acetyl-
transferase], leading to disruption of de novo
sphingolipid biosynthesis. The immediate
consequences thereof are accumulation of the
sphingoid bases sphinganine (Sa) and sphin-
gosine (So), an increase in the Sa to So ratio
(Sa/So), and depletion of complex sphin-
golipids (CSLs) in tissues (Figure 6).
Recognizing the importance of sphingolipids
in cell regulatory processes, including those
related to proliferation and apoptosis
(76,89–91), investigators have proposed that
ceramide synthase inhibition is the critical
mechanistic step in fumonisin toxicity, start-
ing a cascade of molecular events eventually
leading to cytotoxicity or neoplasia.
Fumonisin exposure, sphingolipid effects,
and toxicity are correlated in vivo. Liver and
kidney Sa, So, and Sa/So were increased in
rats fed 15–150 ppm FB1 for 4 weeks (Figure
7) (80), and increases occurred at doses equal
to or less than those causing microscopic
lesions (apoptosis). Importantly, liver and
kidney Sa/So increases were correlated with
the severity of hepatopathy and nephropathy
in rats fed F. moniliforme culture material (71
ppm FB1), water-extracted culture material
(11 ppm FB1), or an alkali-treated (nixtamal-
ized) culture material containing 58 ppm
HFB1 but no measureable FB1 (92,93). 
The role of sphingolipids as mediators of
fumonisin toxicity has not yet been proven,
and other mechanisms may come into play.
For example, several groups have presented
data suggesting that fumonisins cause compo-
sitional or oxidative damage to cellular lipids,
which in turn causes molecular events culmi-
nating in oxidative damage to DNA and other
critical macromolecules (94–99). A more
detailed discussion of molecular mechanism is
beyond the purpose of this review but can be
found elsewhere in this issue (87,100–102).
Reproduction and Teratology
Studies
Javed et al. (103) found that FB1 was
embryotoxic and caused malformations when
injected into chicken eggs. FB1 and HFB1
also inhibited growth of rat embryos exposed
in vitro on gestation day (GD) 9.5 (104).
Under similar conditions, 100 or 300 µM
HFB1 caused neural tube and other malfor-
mations (105). Although useful as screens, in
vitro methods allow direct fetal exposure and
avoid maternal gastrointestinal absorption,
pharmacokinetics, placental transfer, and
other potential barriers of in utero exposure. 
To assess the reproductive effects of F.
moniliforme, male and female Sprague-
Dawley rats were fed culture material of iso-
late MRC 826 providing 0, 1, 10 or 55 ppm
FB1 (106). The culture material was mini-
mally toxic to males (≥ 10 ppm) and females
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products
Figure 6. Simpliﬁed depiction of the de novo synthesis
of sphingolipids. Abbreviations: CSL, complex sphin-
golipids FBx, fumonisins B; SM, sphingomyelin. FBx
inhibit incorporation of the sinto ceramide (Cer), thus
increasinphingoid bases Sa and So g cellular Sa and So,
depleting CSL, and otherwise disrupting sphingolipid
metabolism. Data from Yoo et al. (124).
Figure 7. Tissue Sa/So, a biomarker of fumonisin expo-
sure, was increased in Sprague-Dawley rats
(n = 5/group) fed 15, 50, or 150 ppm FB1 for 4 weeks,
primarily because of increased Sa. Differences in liver
Sa/So were significant (p < 0.05) at 150 ppm in males
and ≥ 50 ppm in females, and differences in kidney
Sa/So were signiﬁcant at ≥ 15 ppm in both sexes, doses
that for both organs were equal to or less than the low-
est dose causing microscopic lesions (arrows). Data
from Voss et al. (58) and Riley et al. (80). 
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Figure 5. Daily subcutaneous injection of FB1 for 5 con-
secutive days increased the number of renal tubular
cells stained in situ by TUNEL, a technique marking
apoptotic nuclei. Values indicate group mean; n = 5. The
difference was statistically signiﬁcant (p < 0.05) at 6.25
mg/kg FB1 but, because of a large standard deviation,
not at 2.25 mg/kg FB1. Microscopic examination of
hematoxylin and eosin-stained kidney specimens yielded
similar results: apoptosis was found in all mice given
2.25 or 6.25 mg/kg FB1, 2–3 mice/group given 0.25–0.75
mg/kg FB1, and none of the controls. Figure adapted
from the data of Sharma et al. (84).
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(55 ppm), as indicated by serum chemistry
ﬁndings and kidney pathology. All reproduc-
tive end points in males, which included tes-
ticular morphology, sperm morphology, and
sperm motility, were unaffected. One half of
the mated females from each group were
examined on GD 15, at which time no differ-
ences among groups were found in the num-
ber of corpora lutea, implantation sites,
resorptions, dead fetuses, and live fetuses per
dam. The remaining females gave birth and
were observed, along with their litters, for 21
days postpartum. Other than a slight decrease
in weight gain (but not absolute weight) of
litters from groups given 10 and 55 ppm FB1,
no differences were found in maternal repro-
ductive or offspring development variables.
Although liver Sa/So of the dams fed 55 ppm
FB1 was signiﬁcantly increased, no differences
in the Sa/So of control and high-dose (55
ppm) fetuses were found on GD 15 (abdomi-
nal slices containing liver and kidney), indi-
cating that fumonisins did not cross the
placenta. This was corroborated in a second
study in which no radiolabel (< 0.02% of the
dose) was found in the fetuses following iv
injection of [14C]FB1 to pregnant females on
GD 15 (106). 
Pregnant rats were given 1.875–15
mg/kg bw purified FB1 on GD 3–16 (107)
and examined on GD 17 and GD 20. FB1
had no effect on maternal reproductive vari-
ables. The high dose (15 mg/kg FB1) was
maternally toxic, causing decreased weight
gain on GD 17, decreased kidney weights,
and increased Sa/So of liver, kidney, and
serum. Sa/So was also increased in livers of
dams given 7.5 mg/kg, kidneys of dams
given ≥ 1.875 mg/kg, and serum of dams
given 7.5 mg/kg FB1. Decreased length and
weight of female fetuses were noted on GD
20. Otherwise, there was no evidence of fetal
toxicity or teratogenicity. The study was
repeated at doses ranging from 6.25 to 50
mg/kg FB1 (108). Apoptosis and other
microscopic findings typical of fumonisins
were found in kidney (≥ 6.25 mg/kg) and
liver (25 or 50 mg/kg). Increased Sa/So was
found in maternal liver (≥ 25 mg/kg), kidney
(≥ 6.25 mg/kg), and serum (≥ 25 mg/kg).
Fetal deaths were increased at 25 and 50
mg/kg, and the number of viable fetuses/dam
(12.0 ± 1.1 vs control value of 14.0 ± 0.5),
fetal length, and fetal weight were decreased
at 50 mg/kg. The incidence of hydrocephalic
fetuses and skeletal anomalies such as wavy
ribs and reduced ossification was increased
somewhat at 50 mg/kg, but no teratogenic
effects were found. Sa/So of fetal tissues were
unchanged at any of the doses studied, sug-
gesting that the fetal effects were indirect and
secondary to maternal toxicity. 
Results of other developmental toxicity
studies (Table 3) generally agree and likewise
suggest that FB1 is not teratogenic but may
be embryotoxic at maternally toxic doses
(109,110). In contrast, Floss et al. (111,112)
concluded that FB1 was a developmental
toxin in hamsters at dosages that were not
maternally toxic. It is possible that there are
species-related differences in maternal
response. However, detailed serum chemical,
histopathologic, or fetal and maternal tissue
sphingolipid evaluations, which may have
revealed maternal toxicity in the hamsters,
were not undertaken. Collins et al. (107,108),
LaBorde et al. (110), and Voss et al. (106)
have shown signiﬁcant organ weight, pathol-
ogy, and sphingolipid effects in dams that
otherwise appear unaffected by FB1. 
Applied Studies Using 
Culture Materials 
FB1 does not occur alone. Co-exposure
undoubtedly occurs with other mycotoxins
and mycotoxin products formed during grain
handling or food preparation. As illustrated
below, F. moniliforme culture material can be a
useful, cost-effective tool for studying how co-
exposure to other mycotoxins or mycotoxin
products influences FB1 toxicity. However,
such experiments should be carefully designed
and results interpreted with caution. Not all F.
moniliforme strains are toxic, and culture mate-
rials are complex mixtures containing biologi-
cally active compounds (both known and
unknown) that may confound results. 
To determine the potential in vivo toxic-
ity of FB2 and FB3, Voss et al. (64) studied
three genetically related F. moniliforme iso-
lates. Isolate M3125 produced FB1, FB2, and
FB3 in the approximate ratio of 1:0.35:0.15.
Isolate 107-R-7 produced FB2 (no detectable
FB1 or FB3), and isolate 397-R-74 produced
FB3 (no FB1 or FB2). Low (4.6–6.9 ppm),
mid (32–53 ppm), and high (219–303 ppm)
levels of culture materials of each isolate were
fed to rats for 3 weeks. All were toxic. Their
effects were qualitatively indistinguishable,
consisting of decreased weight gain, decreased
kidney weights, increased serum chemical
indications of hepatotoxicity, increased Sa/So,
and apoptosis in the liver and kidneys. All
findings were consistent with the effects of
FB1 (57,58), and elevated tissue Sa/So was
correlated with various toxicologic end
points. Thus, hepato- and nephrotoxicities
can be induced by FB1 nonproducing fungi,
and toxicity studies of puriﬁed FB2 and FB3
are warranted.
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Table 3. Summary of selected developmental toxicity studies of FB1 in laboratory species.
Species Dosing Findings and comments References
Fischer 344  0, 30, 60 mg/kg FB1; Fetal: decreased litter weight (approximately 20% reduction at high dose); hypoplasia (delayed or incomplete  (122)
rats by gavage; GD 8–12 ossiﬁcation) of sternebrae and vertebral bodies at 30 and 60 mg/kg.
Maternal: no signiﬁcant weight gain effects.
Comment: other data relevant to maternal toxicity such as pathology, serum chemistry, or sphingolipid proﬁles 
not reported.
Syrian  0, 12, 18 mg/kg FB1; Fetal: increased fetal death and resorption; decreased fetal weight; one litter had fetuses with hooked/curled tails;  (112)
hamsters by gavage; GD 8 and 9 one litter had fetuses with ectodactaly.
Maternal: no weight gain effects. No differences in serum AST and bilirubin. Reference to some hepatic and 
placental pathologic changes.
Comment: dose response of liver and placental pathology not described. Kidney pathology or sphingolipid proﬁles 
(indicators of maternal toxicity) not reported.
New Zealand  0, 0.1, 0.5, 1 mg/kg FB1; Fetal: 13–16% decrease in body weight and decreased kidney and liver weight at 0.5 and 1 mg/kg. Otherwise,  (110)
white rabbits by gavage; GD 3–19 no signiﬁcant ﬁndings. Fetal tissue Sa/So unaffected.
Maternal: mortality increased at ≥ 0.5 mg/kg. Increased Sa/So of liver, kidney, serum, and urine.
Comment: no evidence of teratology or signiﬁcant developmental toxicity in presence of maternal toxicity.
CD-1 mice 0, 12.5, 25, 50, 100 Fetal: increased fetal death (resorptions), decreased fetal weight and increased incidence of hydrocephalus at  (109,123)
mg/kg FB1; by gavage; ≥ 25 mg/kg. No increase in fetal hepatic Sa/So.
GD 7–15 Maternal: mortality at two highest doses. Signiﬁcantly reduced maternal weight gain at 100 mg/kg. Signiﬁcant 
hepatic pathology, increased serum ALT and increased liver Sa/So in dams given ≥ 25 mg/kg. 
Comment: fetal toxicity secondary to maternal toxicity; Sa/So indicates that FB1 does not cross placenta. 
Corroborates results of study on developmental toxicity of F. moniliforme culture material extracts (106)
Abbreviations: AST, aspartate aminotransferase activity; ALT, alanine aminotransferase activity. 
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It has been suggested that fusaric acid,
another mycotoxin commonly produced by
F. moniliforme (51,113), exacerbates fumon-
isin toxicity (114,115). Bacon et al. (116)
demonstrated synergistic embryotoxicity by
simultaneous injection of FB1 and fusaric
acid in ovo. Diets containing F. moniliforme
MRC 826 culture material providing low
(3.4 ppm), slightly higher (18 ppm), or very
high (437 ppm) amounts of FB1 and, at each
fumonisin level, 0, 20, 100, or 400 ppm
fusaric acid were fed to rats for 4 weeks (54).
Dose-related body weight, serum chemical,
liver and kidney pathologies, and renal sphin-
golipid effects typical of fumonisins were
caused by the culture material. No evidence
of synergism was found. Fusaric acid alone up
to 400 ppm in the diet was not toxic, and its
presence did not modify the response of the
animals to the culture material.
Masa flour is made from nixtamalized
corn. During nixtamalization, corn is boiled
under alkaline conditions sufﬁcient to convert
fumonisins to their hydrolyzed forms
(117,118). A study by Hendrich et al. (63)
showed that nixtamalization did not reduce
hepatotoxicity or cancer-promoting activity of
F. proliferatum culture material, even though
FB1 and FB2 were converted to HFB1 and
HFB2. However, others reported that although
cytotoxic in vitro, puriﬁed HFB1 had no effect
in vivo, and they proposed that it was not gas-
trointestinally absorbed (62). To further study
nixtamalization and in vivo toxicity, Voss (92)
fed rats F. moniliforme culture material provid-
ing 71 ppm FB1, water-extracted culture mate-
rial providing about 11 ppm FB1, or a
nixtamalized culture material providing 58
ppm HFB1, but no measurable FB1. After 4
weeks the culture material and the nixtamal-
ized culture material caused the hepatic and
renal lesions typical of fumonisins, though the
nixtamalized material was somewhat less
potent. The water-extracted culture material
elicited a noticeably lesser nephrotoxic
response and was not hepatotoxic. Sa and
Sa/So increases in liver and kidney were
increased in all three groups, and the increases
were correlated with the severity of liver and
kidney injury (93). These results agree with the
in vitro ﬁndings of Norred et al. (119), who
reported that HFB1 inhibited ceramide syn-
thase in precision-cut rat liver slices, but less
potently than FB1. The consequences of
chronic HFB1 exposure remain unknown,
and, given the popularity of masa-based food
products, additional investigations on its
occurrence in foods and its toxicity are needed. 
Summary and Conclusions
In vivo studies of F. moniliforme and fumon-
isins in rodents have shown that FB1 and
probably FB2, FB3, and HFB1 cause the toxic
and pathologic effects of F. moniliforme. These
studies have provided other important data
including the following: a) Gastrointestinal
absorption is low, absorbed fumonisins are
rapidly eliminated, and only minor amounts
are retained in liver and kidney. b) Liver and
kidneys are the two major target organs,
although differences in response occur between
sexes, strains, and species. c) Fumonisins may
have other, more subtle organ-speciﬁc effects;
however, there is no compelling evidence that
the esophagus is a target organ. d) Apoptosis is
the initial and presumably critical event in the
pathogenesis of liver and kidney lesions charac-
terized by simultaneous cell loss and regenera-
tion. e) A key molecular event in fumonisin
cytotoxicity is inhibition of ceramide synthase,
leading to disruption of sphingolipid metabo-
lism and probably of sphingolipid regulatory
function. f ) FB1 does not cross the placenta
and is not teratogenic in laboratory species;
however, fumonisins may be embryotoxic at
maternally toxic doses. g) The use of culture
materials provides a cost-effective means of
studying F. moniliforme and fumonisins, as
long as caution is exercised in study design and
data interpretation. The relationships between
F. moniliforme, fumonisins, and human health
remain unresolved. Undoubtedly, in vivo
investigations in rodents will continue to pro-
vide insight into the effects and modes of
action of these important mycotoxins.
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